Atossa Therapeutics

Atossa Therapeutics is a clinical-stage biopharmaceutical company developing therapies for breast cancer and other aggressive cancers. The company focuses on two primary platforms: selective estrogen receptor modulators (SERMs) that target estrogen-driven breast cancers, and intraductal technology that delivers treatments directly to breast tissue through the milk ducts. This localized delivery approach aims to maximize efficacy while minimizing systemic exposure and side effects.

Atossa's pipeline addresses significant unmet needs in cancer prevention and treatment, particularly for high-risk patients and those with hard-to-treat subtypes. The company's precision oncology strategy emphasizes targeted interventions that match specific cancer characteristics with appropriate therapeutic mechanisms. By combining novel delivery methods with established drug classes, Atossa positions itself within a competitive landscape where differentiation comes from how treatments are administered rather than solely through molecular innovation.

The company serves oncology patients and healthcare providers seeking alternatives to conventional systemic therapies. Atossa's focus on breast tissue-specific delivery represents a distinct approach in a sector increasingly oriented toward precision medicine and patient-centric treatment design.